Contract Manufacturing Industry News
-
Therapure Announces Opening Of Custom Biologics Manufacturing Wing
4/20/2012
Recently marked the official opening of Therapure Biopharma Inc.’s Custom Biologics Manufacturing Wing, which supports the development and manufacture of innovative medical treatments.
-
AMRI Announces Development And Manufacturing Deal With Biota Holdings Limited
4/17/2012
AMRI , a leading global contract research and manufacturing organization, was selected by Biota Holdings Limited , a leading anti-infective drug development company based in Australia, to further develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor. AMRI will provide these services to support a New Drug Application for laninamivir to the United States Food and Drug Administration (FDA).
-
Nimble Approach To Partnerships Will Generate Value For Both CROs And The Pharmaceutical Industry, According To New Study
4/11/2012
As more and more R&D is outsourced by pharmaceutical companies, a study released today provides new insight into how to structure the relevant partnerships for success.
-
BASF And Catalent Join Forces To Solve Bioavailability Challenges
4/9/2012
Catalent Pharma Solutions and BASF have entered into a broad collaboration and Open Alliance to provide solutions to overcome bioavailability challenges of new molecular entities with solubility or permeability challenges.
-
Almac And Affymetrix Announce A Global Distribution Agreement For Almac’s Xcel Array
4/2/2012
Almac recently announced that it has signed an exclusive global distribution deal with Affymetrix, Inc. enabling them to directly sell Almac’s proprietary Xcel array for biomarker discovery, development and delivery worldwide.
-
Quintiles To Quantify Healthcare Decisions
4/2/2012
Quintiles and Archimedes Inc. recently announced an agreement to co-promote clinical and commercial solutions for biopharmaceutical companies to help reduce the time and expense associated with developing and marketing novel therapies.
-
Tarsa Therapeutics Signs Commercial Supply Agreement For Its Ostora Oral Calcitonin Product With QS Pharma
4/2/2012
Tarsa Therapeutics recently announced it has entered into a commercial supply agreement with QS Pharma for the bulk manufacture of its OSTORA oral recombinant salmon calcitonin tablet.
-
ScinoPharm And National Health Research Institutes (NHRI) Announce Jointly Developed Diabetes Drug Approved For Phase I Clinical Trial
3/26/2012
ScinoPharm (TWSE1789), a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, today announced its CRO project, DBPR108, commissioned by the National Health Research Institutes (NHRI), has received approval by Taiwan and the U.S. Food and Drug Administration (FDA) to commence a Phase I clinical trial.
-
Recipharm Contracted By ViroPharma To Complete Full Commercial Manufacture Of DuoCort’s Plenadren
3/19/2012
Recipharm and ViroPharma today signed a commercial contract to initiate supply of Plenadren for named patient use.
-
EMD Millipore Partners With Charles River Laboratories For Improved Viral Clearance Studies
2/28/2012
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, recently announced it will be partnering with Charles River Laboratories International, Inc. of Wilmington, MA, to exclusively license EMD Millipore’s TrueSpike technology.
This website uses cookies to ensure you get the best experience on our website. Learn more